false
0001813814
A1
0001813814
2025-10-29
2025-10-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 29, 2025
MIND MEDICINE (MINDMED) INC.
(Exact Name of Registrant as Specified in its
Charter)
| British Columbia |
|
001-40360 |
|
98-1582438 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
One World Trade Center
Suite 8500
New York, New York |
|
10007 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (212) 220-6633
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common Shares |
|
MNMD |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On October 29, 2025, Mind Medicine (MindMed),
Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) and, as discussed elsewhere in
this Current Report on Form 8-K, posted an updated corporate presentation on its website (the “Presentation”). The Prospectus
Supplement and Presentation disclose the Company’s estimated preliminary financial information of cash, cash equivalents and investments
of approximately $209.1 million as of September 30, 2025.
This estimate of cash, cash equivalents and investments
is preliminary and subject to completion. As a result, this unaudited preliminary financial information reflects the Company’s preliminary
estimate with respect to such information, based on information currently available to the Company’s management, and may vary from
the Company’s actual financial position as of September 30, 2025. The unaudited preliminary cash, cash equivalents and investments
included in the Prospectus Supplement, the Presentation and this Current Report on Form 8-K have been prepared by, and are the responsibility
of, the Company’s management. The Company’s independent registered public accounting firm, KPMG LLP, has not audited, reviewed,
compiled or completed its procedures with respect to such unaudited financial information and, accordingly, KPMG LLP does not express
an opinion or any other form of assurance with respect thereto. It is possible that the Company or its independent registered public accounting
firm may identify items that require the Company to make adjustments to the financial information set forth above.
Item 8.01 Other Events.
On October 29, 2025, the Company posted the Presentation
on its website. A copy of the Presentation is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
|
Description |
| 99.1 |
|
Corporate Presentation, posted October 29, 2025 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
MIND MEDICINE (MINDMED) INC. |
| |
|
|
|
| Date: |
October 29, 2025 |
By: |
/s/ Robert Barrow |
| |
|
|
Name: |
Robert Barrow |
| |
|
|
Title: |
Chief Executive Officer |
